Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Significant Decrease in Short Interest

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) was the target of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totaling 8,994 shares, a decrease of 29.9% from the November 30th total of 12,825 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 99,843 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily trading volume, of 99,843 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.2% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Chemomab Therapeutics in a research report on Monday. Zacks Research lowered Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Finally, Wall Street Zen upgraded Chemomab Therapeutics to a “hold” rating in a report on Saturday, October 11th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Chemomab Therapeutics has an average rating of “Hold” and an average target price of $26.50.

Chemomab Therapeutics Stock Performance

Shares of NASDAQ:CMMB traded up $0.01 on Wednesday, hitting $1.65. 110,554 shares of the company were exchanged, compared to its average volume of 92,349. The company’s 50 day moving average price is $2.49 and its two-hundred day moving average price is $3.30. Chemomab Therapeutics has a one year low of $1.60 and a one year high of $9.84. The firm has a market capitalization of $10.16 million, a price-to-earnings ratio of -0.56 and a beta of 0.50.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.